Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Conatus Pharmaceutic (CNAT)

Conatus Pharmaceutic (CNAT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Conatus Pharmaceutic 16745 W. Bernardo Dr. Suite 250 San Diego CA 92127 USA

P: 858-376-2600 F: 858-558-8920

Description:

Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.

Key Statistics

Overview:

Market Capitalization, $K 18,443
Shares Outstanding, K 33,170
Annual Sales, $ 21,720 K
Annual Net Income, $ -11,390 K
Last Quarter Sales, $ 530 K
Last Quarter Net Income, $ -2,730 K
60-Month Beta 1.84
% of Insider Shareholders 11.30%
% of Institutional Shareholders 15.20%
Float, K 29,422
% Float 88.70%

Growth:

1-Year Return -33.41%
3-Year Return -89.33%
5-Year Return -90.09%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 76.39%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/07/20
Earnings Per Share ttm -0.34
EPS Growth vs. Prev Qtr -25.00%
EPS Growth vs. Prev Year 28.57%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

CNAT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -8.12
Price/Earnings to Growth N/A
Return-on-Equity % -48.22%
Return-on-Assets % -39.32%
Profit Margin % -52.44
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 0.85
Price/Cash Flow N/A
Price/Book 1.05
Book Value/Share 0.61
Interest Coverage 0.00
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar